Greener Journal of Medical Sciences

Excellence and Timeliness


Choose Language


Owhonda et al

By Owhonda G; Nnoka VN; Eli S; Ikenga VO; Wekere FCC; Emeghara GI; Tee GP (2022).

Greener Journal of Medical Sciences

Vol. 12(1), pp. 116-122, 2022

ISSN: 2276-7797

Copyright ©2022, the copyright of this article is retained by the author(s)






Prevalence of COVID–19/HIV-Positive Patients in an Isolation Center in Rivers State, Southern Nigeria.



Owhonda G1; Nnoka VN2; Eli S3; Ikenga VO4; Wekere FCC1; Emeghara GI5; Tee GP5



Department of community Medicine, Rivers State University.1

Department of Pharmacology, Rivers State University.2

Mother, Baby and Adolescent Care Global Foundation.3

Department of Surgery, Rivers State University.4

Department of Human Physiology, Rivers State University.5






Article No.: 030922032

Type: Research



Background: COVID – 19 Infection/Human immunodeficiency Virus (HIV) co–infection is a double tragedy to those infected global. The reason is that those infected with HIV have reduced immunity and at greater risk of contacting COVID –19 infection resulting in higher mortality. The global prevalence of COVID-19 infected persons in people living with HIV (PLHIV)  is 2%.

Aim: This study aims to determine the prevalence of admitted patients with COVID-19/HIV co-infection in an isolation center in Rivers State, South-South region of Nigeria.

Method:  This was a 6 – months cross-sectional study of COVID – 19/HIV-  positive patients at an isolation centre in Rivers State, Southern Nigeria. Polymerase Chain Reaction Test (PCR) was used to confirm those that were COVID-19 positive and HIV. Permission for the study was granted by the Director of Public Health, Rivers State Ministry of Health. The data was analysed with SPSS version 25.

Result: Three hundred and thirty five patients were recruited for the study all of which were COVID-19 positive. There were 105 (44.7) males and 130 (55.3) females. The mean age was 38.4 SD 13.2    and .231(98.3) HIV positive.   There were 1Male positive for HIV and 3 Females positive for HIV.

Conclusion: The study revealed the prevalence of COVID – 19/HIV co-infection as 1.7%. Multi-disciplinary management should be instituted for better outcome. In addition, residents should be encouraged to accept COVID-19 vaccination for improved prognosis for those COVID – 19/HIV co-infection.


Accepted:  09/03/2022

Published: 25/03/2022


*Corresponding Author

Dr. Nnoka V. (MBBS)

E-mail: nnokaalentine@

Phone: 08064843958



Prevalence, COVID –19/HIV co-infection, Rivers State, Southern Nigeria.




Return to Content       







1. Mirzaei H, McFarland W, Karamouzian M and Sharifi H (2020). COVID-19 among people living with HIV: A systematic review. AIDS Behav. 1-8. doi: 10.1007/s10461-020-02983-2


2. United States Agency for International Development (USAID).


3. National Agency for the Control of AIDS (NACA), 2019. Nigeria prevalence rate.


4. Page J, Hinshaw D and McKay B (2021). "In Hunt for Covid-19 Origin, Patient Zero Points to Second Wuhan Market – The man with the first confirmed infection of the new coronavirus told the WHO team that his parents had shopped there". The Wall Street Journal.


5. Zimmer C (2021). "The Secret Life of a Coronavirus – An oily, 100-nanometer-wide bubble of genes has killed more than two million people and reshaped the world. Scientists don't quite know what to make of it". The New York Times.


6. McNeil Jr DG (2020). "Wuhan Coronavirus Looks Increasingly Like a Pandemic, Experts Say". The New York Times. ISSN 0362-4331.


7. World Health Organization (WHO), 2015. World Health Organization Best Practices for the Naming of New Human Infectious Diseases (PDF) (Report). hdl:10665/163636.


8. World Health Organization (WHO), 2020. Novel Coronavirus (2019-nCoV) Situation Report – 1" (PDF).


9. Coronavirus disease 2019 (COVID-19) in the EU/EEA and UK – eight update (PDF) (Report). ecdc. Archived (PDF) from the original on 14 March 2020. Retrieved 19 April, 2020


10. Nigeria COVID-19 update (2021).Nigerian Center for Disease Control (NCDC).


11. Gandhi RT, Lynch JB, and Del Rio C (2020). "Mild or Moderate Covid-19". The New England Journal of Medicine. 383 (18): 1757–1766. doi:10.1056/NEJMcp2009249. PMID 32329974


12. Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferrari M, Wang C-B, Mancini N, Steele S and Adeli K (2020). Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med 58: 1037–1052. doi:10.1515/cclm-2020-0722.


13. Letko M, Marzi A, and Munster V (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol, 5: 562–569. doi:10.1038/s41564-020-0688-y.


14. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J and Qian Z (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun, 11: 1620. doi:10.1038/s41467-020-15562-9.


15. Eli S, Orluwene CG, Oku IY, Bob-Manuel M, Enyinnaya SO, Iyama AC, Nnoka VN and Emeghara GI (2022). Proposed treatment of COVID-19 infection in a poor resource setting – the use of medicinal extract from sunflower seed (Helianthus annuus seed). IJSRA, 05(01), 009-015.


16. Zou X, Chen K, Zou J, Han P,Hao J and Han Z (2020). Single-cell RNA-seq data analysis in the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCOV infection. Front Med;14(2):185-192.


17. Garg S, et al. Clinical trends among US hospitalized with COVID – 19. Ann Intern Med; 174(10): 1409-1419. Doi: 10.7326/M21-1991.


18. Mikami T, Miyashite H, Yanid T, et al (2021). Risk factors for mortality in patients with COVID – 19 in New York City. J GEN INTERN MED; 16:17-26.


19. Amakura Y, Yoshimura M, Yamakami S, and Yoshida T (2013). Isolation of phenolic constituents and characterization of antioxidant makers from sunflower (Helianthus annuus L.) seed extract. Phytochemistry Letters; 6(2): 302 – 305.


20. Kamal J (2011). Quantification of alkaloids, phenols, and flavonoids in sunflower (Helianthus annuus L.). Department of Biotechnology; 10(916): 3149 – 3151


21. Li MY, Li L, Zhang Y and Wang XS (2020). Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 9: 45. doi:10.1186/s40249-020-00662-x.


22. Salehi S, Abedi A, Balakrishnan S, and Gholamrezanezhad A (2020). "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients". AJR. American Journal of Roentgenology. 215 (1): 87–93. doi:10.2214/AJR.20.23034.


23. Whigham LD, Watras AC and Schoeller DA (2007). Efficacy of conjugated linoleic acid for reducing fat mass: a meta – analysis in humans; American Journal of Clinical Nutrition; 85(5):1203 – 1211.


24. Centers for Disease Control and Prevention (2020).


25. Gao F, Bailes E, Robertson D.L et al. (1999). Origin of HIV-1 in the chimpanzee pan troglodytes troglodytes. Nature, 397(6718):436-41.


26. Powell MK, Benková K, Selinger P, Dogoši M, Kinkorová Luňáčková I, Koutníková H, Laštíková J, Roubíčková A, Špůrková Z, Laclová L, Eis V, Šach J and Heneberg P (2016). "Opportunistic Infections in HIV-Infected Patients Differ Strongly in Frequencies and Spectra between Patients with Low CD4+ Cell Counts Examined Postmortem and Compensated Patients Examined Antemortem Irrespective of the HAART Era". PLOS ONE. 11 (9) doi:10.1371/journal.pone.0162704


27. World Health Organization (2021). HIV/AIDS.


28. Cunningham AL, Donaghy H, Harman AN, Kim M and Turville SG (2010). "Manipulation of dendritic cell function by viruses". Current Opinion in Microbiology. 13 (4): 524–9. doi:10.1016/j.mib.2010.06.002.


29. Garg H, Mohl J and Joshi A (2012). "HIV-1 induced bystander apoptosis". Viruses. 4 (11): 3020–43. doi:10.3390/v4113020


30. Kumar V (2012). Robbins Basic Pathology (9th ed.). p. 147. ISBN 978-1-4557-3787-1.


31. Karmen-Tuohy S, Carlucci P.M, Zervou F.N, Zacharioudakis I.M, Rebick G, Klein E, Reich J, Jones S, and Rahimian J (2020). Outcomes among HIV-Positive patients hospitalized with COVID-19. J Acquir Immune Defic Syndr; 85(1):6-10. DOI; 10.1097/QAI.0000000000002423.


32. Nagarakanti S.R, Okoh A.K and Bishburg E (2021). Clinical outcomes of patients with COVID-19 and HIV coinfection. J Med Virol, 93(3): 1687-1693. DOI: 10.1002/jmv.26533.


33. Oyelade T, Algaltani  JS, Hjazi AM, Li A, Kamila A;  Raya R P. Global and Regional Prevalence and Outcomes of COVID – 19 in people living with HIV: A Systematic Review and Meta – Analysis. Trop Med. Infect Dis. 2022 3; 7 (2): 22.


34. Algatitan JS, Aldhahiv AM, Oyelade T, Alghamdi SM, Almamary AS.  Smoking Cessation during COVID - 19. The top to – do list. Prim. Care Respire. Med 2021; 31: 1-3.


35. Yang J, Zheng Y, Guox, Puk, Chen Z, Guo Q, JiR, Wang Y Zhon Y. Prevalence of Comorbidities in the Novel Wuhan Coronanrns (Covid – 19) infection: A Systematic Review and Meta – Analysis, Int. J Infect. Dis 2020: 94: 91-95.


36. Seyed Alinghi S, et al. Prevalence of Covid – 19 like Symptoms among people living with HIV and using Anti Retroviral Therapy for  Preventing ad Treatment. Curr HIV Resp. 2020; 18(5): 373 – 380.


37. Shekhar al. Coronavirus Disease of 2019 in patients with well – Controlled Human Immunodeficiency Virus on Antiretroviral Therapy. J Acquire Immune Defic Syn 2020; 85 (1): e1 – e4.


38. Seyed Alirighi  et al. Prevalence of Covid – 19 like Symptoms among People Living with HIV, and using Antiretroviral Therapy fo Prevention and Treatment Curr HIV Res 2020; 18 (5): 373 – 380.


39. The Virus That Changed Spain. Impact of COVID – 19 on people with HIV. Ballester – Amal. R, Gil –llaria M. Https://www.ncbi:nlm.nlm.Gov    (accessed 9/3/2022)




Cite this Article: Owhonda G; Nnoka VN; Eli S; Ikenga VO; Wekere FCC; Emeghara GI; Tee GP (2022). Prevalence of COVID–19/HIV-Positive Patients in an Isolation Center in Rivers State, Southern Nigeria. Greener Journal of Medical Sciences, 12(1): 116-122.


Call for Papers

Call for Scholarly Articles

Authors from around the world are invited to send scholarly articles that suits the scope of this journal. The journal is currently open to submissions and will process and publish articles monthly in two yearly issues.

The journal is centered on quality and goes about its processes in a very timely fashion. Seasoned editors/reviewers will be consulted to review each article(s), profer quality evaluations and polish the articles with expertise before publication.

Simply send your article(s) as an e-mail attachment to or



Login Form

Other Journals